ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
36 announcements
Invicta Diagnostic Limited held its 1st EGM on April 17, 2026. Shareholders approved the regularisation of Mr. Rohit Prakash Srivastava as Whole-Time Director (Finance) and various material related party transactions. A special resolution was also passed to modify the objects and terms of utilisation for the company's IPO proceeds.
Invicta Diagnostic Limited submitted a compliance certificate for the quarter and year ended March 31, 2026. The company certified that Regulation 27(2) of SEBI LODR is not applicable because its shares are listed on the NSE Emerge (SME) Exchange. This is a routine regulatory filing for SME-listed entities.
Invicta Diagnostic Limited submitted a compliance certificate for the year ended March 31, 2026, regarding its Structured Digital Database. The certificate, issued by a Practicing Company Secretary, confirms the company maintained a non-tamperable database in accordance with SEBI PIT Regulations.
Invicta Diagnostic Limited is acquiring a 95% stake in Nashik-based Vinchurkar Diagnostics Private Limited for ₹7.60 Crore. The cash deal occurs in two tranches ending October 2026. This acquisition marks Invicta's entry into the Nashik market, expanding its diagnostic network beyond the Mumbai Metropolitan Region.
Invicta Diagnostic Limited will acquire a 95% stake in Vinchurkar Diagnostics Private Limited for ₹7.6 Crore. The transaction will be executed in two tranches, with 51% acquired by May 2026 and the remainder by October 2026. The definitive agreements are scheduled for execution on April 11, 2026.
Invicta Diagnostic Limited has approved the acquisition of up to 95% stake in Vinchurkar Diagnostics Private Limited for ₹7.6 Crore. The transaction will be executed in two tranches by October 2026. This acquisition aims to expand Invicta's diagnostic service presence in Nashik, Maharashtra.